The path from a medical college in New Delhi to one of the most prestigious academic appointments in American medicine is rarely straightforward. Ravi Vij followed that journey while building a career dedicated to understanding and treating blood cancers. The Indian-origin physician-scientist was recently named the inaugural Jeffrey S. and Prue H. Gershman Distinguished Professor at Washington University School of Medicine in St. Louis, a recognition of his contributions to cancer research, patient care and medical education. The appointment highlights a career that has helped advance treatment options for multiple myeloma and other blood cancers while establishing Vij as one of the leading figures in his field.
Ravi Vij’s journey from New Delhi to the forefront of blood cancer treatment
Ravi Vij’s medical journey began at Maulana Azad Medical College in New Delhi, one of India’s most respected medical institutions. After completing his medical education, he moved to the United States for advanced training in oncology, haematology and bone marrow transplantation at Washington University School of Medicine.He joined the university’s faculty in 2000 and steadily built a reputation as both a clinician and researcher. Over the years, he became a key figure in WashU Medicine’s cancer programme, helping strengthen its standing in blood cancer research and treatment.Much of Vij’s career has centred on multiple myeloma, a cancer that develops in plasma cells found within bone marrow. The disease remains one of the most common forms of blood cancer and has long presented significant challenges for doctors and researchers.During the past two decades, treatment options for multiple myeloma have improved dramatically. Advances in immunotherapy, targeted drugs and stem cell transplantation have extended survival rates and improved quality of life for many patients. Vij has been among the physician-scientists contributing to that progress through both clinical care and research.His work has focused on understanding the biological mechanisms of blood cancers and identifying better ways to treat them.
Leading research that changed treatment approaches
Vij has spent years leading clinical trials that explored new therapies for blood cancers. Several of these studies examined innovative immunotherapy approaches and stem cell transplant strategies that later became part of standard treatment practices.At Siteman Cancer Center, where he treats patients and conducts research, Vij has focused on improving the understanding of multiple myeloma and related blood disorders. His research has helped advance knowledge of how these diseases develop and respond to treatment.The findings from such studies contribute to the growing field of precision medicine, which seeks to tailor therapies to the unique characteristics of individual patients.
More than 200 scientific publications
Throughout his career, Vij has authored more than 200 peer-reviewed scientific papers focused on multiple myeloma, stem cell transplantation, immunotherapy and related blood disorders.His publications have contributed to a broader understanding of blood cancers and informed treatment decisions in cancer centres around the world. This body of work has helped establish him as a respected voice within the international oncology community.
A leader in stem cell transplantation
Stem cell transplantation remains one of the most important treatment options for several blood cancers. The procedure involves replacing damaged bone marrow with healthy blood-forming stem cells, often after intensive chemotherapy.Vij has played a significant role in advancing transplantation techniques and improving outcomes for patients undergoing these complex treatments. His contributions helped strengthen Washington University School of Medicine’s reputation as a major centre for stem cell transplantation and cellular therapies.University leaders have credited his work with supporting the institution’s growth in areas such as immunotherapy and advanced cancer care.
Mentor, teacher and academic leader
Research achievements are only one part of Vij’s professional legacy. He has also dedicated considerable time to mentoring young physicians and scientists.Over the course of his career, he has mentored 25 early-career researchers and medical trainees, helping prepare the next generation of specialists in oncology and haematology. His commitment to education earned him the Teacher of the Year Award from WashU Medicine’s Haematology and Oncology Fellowship Program in 2007.Many of the physicians trained under his supervision have gone on to build successful careers in cancer medicine and research.
Recognised across the oncology community
Vij’s expertise has earned recognition far beyond Washington University.He has held leadership positions with the American Society of Clinical Oncology and the American Society of Hematology, two organisations that play major roles in shaping cancer research and treatment standards.He currently serves as senior editor of the journal Clinical Lymphoma, Myeloma and Leukemia, where he helps oversee the publication of new scientific findings and emerging research in the field.These leadership roles reflect the influence he has developed within the broader oncology community.
What the distinguished professorship means
Endowed professorships are among the highest honours awarded by American universities. They are typically reserved for faculty members who have demonstrated exceptional achievements in research, teaching and public service.The Jeffrey S. and Prue H. Gershman Distinguished Professorship was established through a philanthropic gift from St. Louis benefactors Jeffrey and Prue Gershman. By naming Vij as its inaugural holder, WashU Medicine recognised both his scientific accomplishments and his impact on patient care.The professorship will also help support future research efforts aimed at developing more effective therapies for blood cancers.
A career dedicated to improving patient outcomes
Ravi Vij’s appointment represents another milestone in a career defined by scientific discovery, clinical excellence and mentorship. From his beginnings as a medical student in New Delhi to becoming one of America’s leading blood cancer specialists, his work has remained focused on improving outcomes for patients facing life-threatening diseases.As advances in immunotherapy, cellular medicine and precision oncology continue to reshape cancer care, Vij remains among the researchers helping drive those changes. His latest honour serves as recognition of both a distinguished career and the continuing impact of his work on the future of blood cancer treatment.
